Treatment of Iron Deficiency Anemia

First-Line Treatment

• The American Gastroenterological Association recommends ferrous sulfate 200 mg once daily as the preferred oral iron formulation due to its effectiveness and low cost 1, 2
• Once-daily dosing is recommended over multiple daily doses to improve tolerance while maintaining effectiveness 1
• Adding vitamin C (ascorbic acid) can enhance iron absorption when response is poor 1, 3, 2
• Oral iron therapy should be continued for 3 months after correction of anemia to replenish iron stores 3, 2
• Hemoglobin is expected to rise by approximately 2 g/dL after 3-4 weeks of treatment 3, 2
• Alternative oral iron formulations, such as ferrous gluconate and ferrous fumarate, may be better tolerated in some patients but have similar effectiveness 3, 2

Indications for Intravenous Iron

• Intravenous iron should be used in patients who cannot tolerate oral iron despite trying at least two different oral preparations 3, 2
• Intravenous iron is indicated for patients with inadequate response to oral iron therapy 1
• Conditions affecting iron absorption, such as inflammatory bowel disease with active inflammation, may require intravenous iron 1

Intravenous Iron Options

• Prefer IV iron formulations that can replace iron deficits with 1-2 infusions 1, 4
• Iron dextran can be given as a total dose infusion but carries a higher risk of anaphylaxis 5

Monitoring and Follow-up

• Hemoglobin and red cell indices should be monitored at 3-month intervals for the first year after correction, then again after another year 3, 2
• Additional iron supplementation should be provided if hemoglobin or MCV falls below normal 3
• Further investigation is recommended if anemia doesn't resolve within 6 months 3, 4

Special Populations

• For patients with inflammatory bowel disease, iron deficiency should be treated by determining the underlying cause and addressing it 1, 4
• For pregnant women, oral iron supplementation is first-line therapy, with IV iron indicated during second and third trimesters if needed 6

Common Pitfalls to Avoid

• Failing to treat the underlying cause of iron deficiency while supplementing iron 3, 2
• Continuing oral iron despite poor tolerance or inadequate response 1, 4
• Using multiple daily doses of oral iron, which increases side effects without improving efficacy 1, 4
• Overlooking the need for vitamin C supplementation to enhance iron absorption 1, 2
• Failing to continue iron therapy for 3 months after correction of anemia 3, 2

Iron Deficiency Anemia Treatment Guidelines

Indications for Intravenous Iron

• The American Gastroenterological Association recommends intravenous iron for patients with inflammatory bowel disease and severe anemia (Hb <10 g/dL) 7, 8
• The American Gastroenterological Association suggests intravenous iron for patients with conditions affecting iron absorption, such as inflammatory bowel disease with active inflammation, celiac disease with ongoing gluten exposure, and post-bariatric surgery 9, 10, 8
• Intravenous iron is recommended for patients who cannot tolerate oral iron despite trying at least two different oral preparations, or have an inadequate response to oral iron therapy after 4 weeks 11

Special Populations

Pregnant Women

• The Centers for Disease Control and Prevention recommends starting oral low-dose (30 mg/day) iron supplements at the first prenatal visit, and prescribing an oral dose of 60-120 mg/day of iron for anemia treatment 11, 12
• The Centers for Disease Control and Prevention suggests referring pregnant women with Hb <9.0 g/dL for further medical evaluation 11, 12

Inflammatory Bowel Disease

• The European Crohn's and Colitis Organisation recommends intravenous iron as first-line treatment in patients with clinically active IBD and Hb <10 g/dL 7, 8
• Treating underlying inflammation can enhance iron absorption and reduce iron depletion in patients with inflammatory bowel disease 8

Celiac Disease

• The American Gastroenterological Association recommends ensuring adherence to a gluten-free diet to improve iron absorption, and considering intravenous iron therapy if iron stores do not improve with oral supplementation 9, 8

Treatment of Iron Deficiency Anemia

Initial Oral Iron Therapy

• The American Gastroenterological Association recommends starting with oral ferrous sulfate 200 mg once daily, which is the preferred first-line treatment due to its effectiveness and low cost 13
• Ferrous sulfate 200 mg once daily is the recommended formulation rather than three-times-daily dosing, as once-daily or alternate-day dosing improves tolerability while maintaining effectiveness 13
• Alternative oral formulations, such as ferrous gluconate and ferrous fumarate, are equally effective if ferrous sulfate is not tolerated 14
• Adding vitamin C supplementation enhances iron absorption when response to oral iron is poor 15, 14
• Oral iron therapy should be continued for 3 months after anemia correction to fully replenish iron stores 14

Expected Response and Monitoring

• Hemoglobin should rise by approximately 2 g/dL after 3-4 weeks of treatment 14
• If no response occurs within 4 weeks, assess for non-adherence, malabsorption, or ongoing blood loss 15
• Monitor hemoglobin and red cell indices every 3 months for the first year, then again after another year 14

When to Switch to Intravenous Iron

• Intravenous iron should be used when oral iron fails or is contraindicated, with specific indications including intolerance to at least two different oral iron preparations, inflammatory bowel disease with active inflammation, post-bariatric surgery patients, and celiac disease with inadequate response to oral iron 13
• Inflammatory bowel disease with active inflammation, especially if hemoglobin is less than 10 g/dL, is an absolute indication for IV iron 13
• Post-bariatric surgery patients with disrupted duodenal iron absorption should be treated with IV iron 13
• Celiac disease with inadequate response to oral iron despite gluten-free diet adherence is an indication for IV iron 13
• Ongoing gastrointestinal blood loss exceeding oral replacement capacity is an indication for IV iron 13

Special Population Considerations

• In patients with inflammatory bowel disease, treat active inflammation first to enhance iron absorption and reduce iron depletion 13
• In patients with portal hypertensive gastropathy, start with oral iron supplementation initially and switch to IV iron if ongoing bleeding persists without response to oral therapy 13
• In patients with celiac disease, ensure strict adherence to gluten-free diet to improve iron absorption and progress to IV iron if oral supplementation fails despite dietary compliance 13
• In post-bariatric surgery patients, IV iron is preferred due to disrupted duodenal absorption mechanisms 13

Common Pitfalls to Avoid

• Do not continue oral iron indefinitely without response - reassess after 4 weeks and switch to IV iron if hemoglobin fails to rise 15
• Do not use multiple daily doses - once-daily or alternate-day dosing is better tolerated with similar efficacy 13
• Do not stop iron therapy when hemoglobin normalizes - continue for 3 months to replenish stores 14
• Do not overlook vitamin C supplementation when oral iron response is suboptimal 15, 14
• Do not fail to identify and treat the underlying cause of iron deficiency while supplementing 15
• Do not use parenteral iron as first-line unless specific contraindications to oral therapy exist 15

Failure to Respond

• If anemia does not resolve within 6 months despite appropriate iron therapy, reassess for ongoing blood loss 14
• Evaluate for malabsorption syndromes 15
• Consider further gastrointestinal investigation 15
• Verify patient adherence to therapy 16

Treatment of Iron Deficiency Anemia

Immediate Treatment Approach

• The American Gastroenterological Association recommends starting oral ferrous sulfate 200 mg once daily, which is the preferred first-line treatment for patients with severe iron deficiency anemia, as once-daily dosing improves tolerability while maintaining effectiveness 17
• Oral iron therapy should be taken on an empty stomach for optimal absorption, though taking with food is acceptable if gastrointestinal side effects occur 18
• Adding vitamin C (ascorbic acid) 500 mg with the iron dose enhances absorption, particularly important given severely low iron saturation 19, 18
• Alternative formulations (ferrous gluconate or ferrous fumarate) are equally effective if ferrous sulfate is not tolerated 19, 18

Expected Response and Monitoring

• Hemoglobin should rise by approximately 2 g/dL after 3-4 weeks of treatment, according to the European Society for Medical Oncology 19

When to Switch to Intravenous Iron

• Consider IV iron if the patient meets certain criteria, including intolerance to at least two different oral iron preparations, as recommended by the American College of Gastroenterology 17, 19
• Conditions affecting iron absorption, such as inflammatory bowel disease with active inflammation, celiac disease, or post-bariatric surgery, may require IV iron therapy 17, 18

Identify and Treat Underlying Cause

• The European Society of Gastrointestinal Endoscopy recommends investigating the source of iron deficiency, including assessing menstrual blood loss in premenopausal women and performing gastrointestinal evaluation with upper endoscopy and colonoscopy in men and postmenopausal women 19
• Celiac disease screening with antiendomysial antibody and IgA measurement should be considered, as recommended by the American Gastroenterological Association 19

Common Pitfalls to Avoid

• The American College of Gastroenterology advises against prescribing multiple daily doses of oral iron, as this increases side effects without improving efficacy, and against stopping iron therapy when hemoglobin normalizes, as treatment should continue for 3 months to replenish stores 19, 18

Failure to Respond

• If anemia does not resolve within 6 months despite appropriate iron therapy, reassess for ongoing blood loss, evaluate for malabsorption syndromes, and consider further gastrointestinal investigation, as recommended by the European Society for Medical Oncology 19
• Verify patient adherence to therapy and consider hematology consultation for complex cases, according to the American College of Gastroenterology 19, 18

Management of Iron Deficiency Anemia

Oral Iron Supplementation

• Adding ascorbic acid (vitamin C) 500 mg with each iron dose enhances absorption, particularly critical given the severely low transferrin saturation, according to the European Society of Gastrointestinal Endoscopy 20, 21
• Alternative formulations (ferrous gluconate or ferrous fumarate) are equally effective if ferrous sulfate is not tolerated, as recommended by the American Gastroenterological Association 20, 22

Investigation of Underlying Cause

• Assessing menstrual blood loss first is crucial, as menorrhagia, pregnancy, and breastfeeding are responsible for iron deficiency in 5-10% of menstruating women, according to the American College of Obstetricians and Gynecologists 21, 22
• Considering pictorial blood loss assessment charts, which have 80% sensitivity and specificity for detecting menorrhagia, is a useful diagnostic tool, as suggested by the European Society of Gastrointestinal Endoscopy 21, 22
• Screening for celiac disease with antiendomysial antibody and IgA measurement is essential, as this is a common cause of malabsorption in younger patients, according to the North American Society for the Study of Celiac Disease 21, 22

When to Pursue Gastrointestinal Investigation

• Gastrointestinal endoscopy is only indicated if the patient has upper GI symptoms, as recommended by the American Society for Gastrointestinal Endoscopy 21, 22
• Colonic investigation should only be performed if there are specific indications, such as rectal bleeding, family history of colon cancer, or alarm symptoms, according to the American College of Gastroenterology 21, 22

When to Switch to Intravenous Iron

• Intolerance to at least two different oral iron preparations is a specific indication for intravenous iron therapy, as recommended by the European Society of Gastrointestinal Endoscopy 20
• Parenteral iron is painful, expensive, and carries risk of anaphylactic reactions, according to the American Medical Association 20, 21
• The rise in hemoglobin is no quicker than with oral preparations, as noted by the European Society of Gastrointestinal Endoscopy 20, 21

Critical Pitfalls to Avoid

• Overlooking vitamin C supplementation when oral iron response is suboptimal can significantly reduce absorption, as noted by the European Society of Gastrointestinal Endoscopy 20, 21
• Failing to identify and treat the underlying cause while supplementing iron is crucial, as recommended by the American College of Physicians 20, 21

Failure to Respond

• Assessing for continued blood loss and evaluating for malabsorption syndromes are essential steps if no improvement is seen after 4 weeks, according to the European Society of Gastrointestinal Endoscopy 20, 21
• Reassessing for ongoing blood loss and considering further gastrointestinal investigation are necessary if anemia persists at 6 months, as recommended by the American Gastroenterological Association 21, 22

Treatment of Iron Deficiency Anemia

Introduction to Iron Deficiency Anemia Treatment

• The European Crohn's and Colitis Organisation recommends that hemoglobin should rise by approximately 2 g/dL after 3-4 weeks of treatment, representing an acceptable speed of response 23
• The American Gastroenterological Association suggests that intolerance to at least two different oral iron preparations is an indication for intravenous iron therapy 24

Intravenous Iron Therapy

• The American Gastroenterological Association recommends considering IV iron if the patient has hemoglobin below 10 g/dL in patients with inflammatory bowel disease 23, 24
• The European Crohn's and Colitis Organisation suggests that IV iron is first-line treatment in patients with clinically active IBD and hemoglobin <10 g/dL 23, 24
• The Clinical Gastroenterology and Hepatology guideline recommends that ferric carboxymaltose (500-1000 mg single doses, can be delivered within 15 minutes) is a preferred IV iron formulation 23
• The Journal of Crohn's and Colitis recommends avoiding iron dextran preparations due to higher risk of anaphylaxis requiring test doses 23

Special Population Considerations

• The Clinical Gastroenterology and Hepatology guideline suggests that IV iron is preferred in post-bariatric surgery patients due to anatomic considerations affecting duodenal absorption 24
• The American Gastroenterological Association recommends that a single dose of IV iron is more effective and better tolerated than oral ferrous fumarate or ferrous gluconate in post-bariatric surgery patients 24
• The European Crohn's and Colitis Organisation suggests that IV iron is more effective and better tolerated than oral iron in IBD patients (odds ratio 1.57 for achieving 2.0 g/dL hemoglobin increase) 24

Management of Iron Deficiency Anemia

Diagnosis and Treatment

• The European Society of Gastroenterology recommends that iron saturation below 20% indicates severe iron depletion, as seen in this patient with an iron saturation of 8.49% 25
• The American Gastroenterological Association suggests that a Total Iron-Binding Capacity (TIBC) of 225 is elevated, indicating iron deficiency 26
• The World Health Organization states that ferritin levels up to 100 ng/mL can still indicate iron deficiency in the presence of inflammation, and values between 30-100 ng/mL suggest combined iron deficiency and anemia of chronic disease 27
• The National Institute of Diabetes and Digestive and Kidney Diseases recommends that vitamin C supplementation significantly enhances iron absorption, especially critical with low iron saturation 25, 26

Treatment Protocol

• The American College of Gastroenterology recommends continuing iron therapy for 3 months after hemoglobin normalizes to fully replenish iron stores 26, 25
• The European Society of Gastroenterology suggests that hemoglobin should rise by approximately 2 g/dL after 3-4 weeks of treatment 27, 25

Investigation of Underlying Cause

• The American Gastroenterological Association recommends assessing menstrual blood loss first in premenopausal women, as menorrhagia, pregnancy, and breastfeeding account for iron deficiency in 5-10% of menstruating women 25
• The World Health Organization states that screening for celiac disease with antiendomysial antibody and IgA measurement is essential, as it is a common cause of malabsorption 26

Monitoring Protocol

• The National Institute of Diabetes and Digestive and Kidney Diseases recommends rechecking hemoglobin at 4 weeks, as failure to rise by 2 g/dL indicates poor compliance, continued blood loss, or malabsorption 25
• The European Society of Gastroenterology suggests monitoring every 3 months for the first year, then again after another year 25

Iron Deficiency Anemia Treatment Guidelines

First-Line Oral Iron Treatment

• The American Gastroenterological Association recommends starting with ferrous sulfate 200 mg (containing 65 mg elemental iron) taken once daily for treating iron deficiency anemia, as it is the most cost-effective and equally efficacious as all other oral iron formulations 28
• Once-daily dosing is superior to multiple daily doses because it improves tolerance while maintaining equal or better iron absorption, according to the American Gastroenterological Association 28
• No single oral iron formulation has any therapeutic advantage over another—the choice is purely economic, as stated by the American Gastroenterological Association 28

Alternative Oral Formulations

• Ferrous fumarate (106 mg elemental iron per 325 mg tablet) and ferrous gluconate (38 mg elemental iron per 325 mg tablet) are alternative oral formulations that are equally effective but typically more expensive, according to the International Society of Nephrology and the European Society of Gastrointestinal Endoscopy 29, 30

Optimizing Oral Iron Absorption

• Adding vitamin C (ascorbic acid) 500 mg with each iron dose enhances absorption, as recommended by the American Gastroenterological Association and the European Society of Gastrointestinal Endoscopy 28, 30

Dosing Schedule for Maximum Effectiveness

• The American Gastroenterological Association recommends giving iron once daily at most—never multiple times per day, to maximize effectiveness and minimize side effects 28

When to Switch to Intravenous Iron

• Intravenous iron should replace oral therapy in patients with intolerance to at least two different oral iron preparations, failure of ferritin levels to improve after 4 weeks of compliant oral therapy, active inflammatory bowel disease with hemoglobin <10 g/dL, post-bariatric surgery patients, and those with ongoing gastrointestinal blood loss exceeding oral replacement capacity, as recommended by the American Gastroenterological Association and the European Crohn’s and Colitis Organisation 28, 31

Preferred IV Iron Formulations

• The American Gastroenterological Association recommends choosing IV iron preparations that replace iron deficits in 1-2 infusions rather than multiple infusions, to minimize the risk of anaphylaxis and infusion reactions 28

Treatment Duration and Monitoring

• The European Society of Gastrointestinal Endoscopy recommends continuing oral iron therapy for 3 months after hemoglobin normalizes to fully replenish iron stores, and monitoring hemoglobin and red cell indices every 3 months for the first year, then again after another year 30

Special Population Considerations

• The Centers for Disease Control and Prevention recommend starting with oral low-dose iron 30 mg/day at first prenatal visit for prevention, and treating anemia with 60-120 mg/day elemental iron in pregnant women 32
• The European Crohn’s and Colitis Organisation recommends IV iron as first-line treatment when hemoglobin <10 g/dL with active inflammation in patients with inflammatory bowel disease 31
• The American Gastroenterological Association recommends IV iron as the preferred treatment option due to disrupted duodenal absorption mechanisms in post-bariatric surgery patients 28

Iron Deficiency Anemia Treatment Guidelines

Special Population Considerations

• The Centers for Disease Control and Prevention recommends starting oral low-dose iron 30 mg/day at the first prenatal visit for prevention in pregnant women 33
• The Centers for Disease Control and Prevention recommends treating anemia with 60-120 mg/day elemental iron in pregnant women 33
• The Centers for Disease Control and Prevention suggests referring pregnant women with hemoglobin <9.0 g/dL for further medical evaluation 33
• If anemia does not respond after 4 weeks despite compliance, the Centers for Disease Control and Prevention recommends further evaluation with MCV, RDW, and serum ferritin in pregnant women 33
• The Centers for Disease Control and Prevention notes that in women of African, Mediterranean, or Southeast Asian ancestry, mild anemia unresponsive to iron therapy may be due to thalassemia minor or sickle cell trait 33

Iron Deficiency Anemia Management

Initial Treatment

• The American Gastroenterological Association recommends starting oral ferrous sulfate 200 mg (65 mg elemental iron) once daily immediately, without delaying treatment while awaiting diagnostic workup, unless colonoscopy is scheduled within days 34, 35
• Once-daily dosing of ferrous sulfate is superior to multiple daily doses, as it improves tolerance while maintaining equal or better iron absorption due to hepcidin regulation 34, 35, 36
• Alternative formulations, such as ferrous fumarate 106 mg elemental iron or ferrous gluconate 38 mg elemental iron, are equally effective if ferrous sulfate is not tolerated 34, 36

Optimize Absorption

• Adding vitamin C (ascorbic acid) 500 mg with each iron dose enhances absorption 36
• If not tolerated daily, switching to every-other-day dosing increases fractional iron absorption and improves tolerance with similar efficacy 34, 35

Expected Response and Monitoring

• Check hemoglobin at 4 weeks, expecting a rise of approximately 2 g/dL 34
• Continue oral iron for 3 months after hemoglobin normalizes to fully replenish iron stores 34, 35

Special Population Considerations

• In patients with active inflammatory bowel disease, treat active inflammation first to enhance iron absorption and reduce iron depletion, and use IV iron as first-line if hemoglobin <10 g/dL with active inflammation 36
• In post-bariatric surgery patients, IV iron is preferred due to disrupted duodenal absorption mechanisms 36
• In patients with celiac disease, ensure strict adherence to gluten-free diet to improve iron absorption, and progress to IV iron if oral supplementation fails despite dietary compliance 36

Critical Pitfalls to Avoid

• Do not prescribe multiple daily doses, as this increases side effects without improving efficacy due to hepcidin-mediated absorption blockade 34, 35, 36
• Do not stop iron therapy when hemoglobin normalizes, but continue for 3 months to replenish stores 34, 35

Iron Deficiency Treatment with Intravenous Iron

Guideline Support for IV Iron in Oral Iron Intolerance

• The American Gastroenterological Association recommends intravenous iron for patients with iron deficiency who cannot tolerate oral iron, regardless of the presence of anemia, with a strength of evidence based on clinical guidelines 37, 38, 39
• The guideline does not distinguish between iron deficiency with or without anemia when oral intolerance is the indication for IV therapy, as stated by the American Gastroenterological Association 37

Choosing the Right IV Iron Formulation

• The American Gastroenterological Association prefers IV iron formulations that can replace iron deficits with 1-2 infusions rather than multiple infusions, such as iron dextran 37, 38

Iron Dextran Considerations

• Iron dextran can be given as a total dose infusion in a single session, making it convenient for complete iron repletion, according to the Gut journal 40
• The risk of true anaphylaxis with iron dextran is very rare (0.6-0.7%), and most reactions are complement activation-related pseudo-allergy (infusion reactions) rather than true anaphylaxis, as reported in Clinical Gastroenterology and Hepatology and Gut 37, 40
• Resuscitation facilities must be available when administering any IV iron formulation, including iron dextran, as recommended in the Gut journal 40

Alternative IV Iron Options

• Iron sucrose requires multiple visits for infusion, with a maximum of 200 mg per infusion over 10 minutes, as stated in the Gut journal 40
• All IV iron formulations have similar overall safety profiles, according to the American Gastroenterological Association 37

Clinical Considerations

• The American Gastroenterological Association advises against delaying IV iron therapy until anemia develops, as iron deficiency itself causes symptoms that warrant treatment 37
• It is essential to investigate the underlying cause of iron deficiency while treating with IV iron, as recommended in the Gut journal 40
• The American Gastroenterological Association notes that most IV iron reactions are infusion reactions that respond to slowing the infusion rate, rather than true anaphylaxis requiring epinephrine 37

Iron Deficiency Anemia Treatment Guidelines

Introduction to Iron Formulations

• The American Gastroenterological Association recommends ferrous sulfate as the preferred first-line treatment for iron deficiency anemia due to its higher elemental iron content and lower cost, with no evidence of superior efficacy or tolerability for ferrous gluconate 41

Elemental Iron Content and Cost-Effectiveness

• Ferrous sulfate is consistently the least expensive oral iron formulation available, making it the most cost-effective choice, with ferrous sulfate 325 mg tablets containing 65 mg of elemental iron 41, 42

Evidence-Based Dosing

• The recommended dose is ferrous sulfate 200 mg (approximately 65 mg elemental iron) once daily, which improves tolerance while maintaining equal or better iron absorption compared to multiple daily doses 41
• Once-daily dosing is preferred because hepcidin levels remain elevated for 48 hours after iron intake, blocking further absorption 41

Tolerability and Side Effects

• Ferrous gluconate may be tried if ferrous sulfate causes intolerable gastrointestinal side effects, such as constipation, diarrhea, or nausea, although there is no clinical trial evidence that ferrous gluconate is better tolerated than ferrous sulfate 41, 43

Optimizing Oral Iron Therapy

• Adding vitamin C (ascorbic acid) 500 mg with each iron dose enhances absorption, especially when response is suboptimal 41, 42
• Taking iron on an empty stomach is optimal for absorption, but taking with food is acceptable if gastrointestinal side effects occur 41

Expected Response and Monitoring

• Hemoglobin should rise by approximately 2 g/dL after 3-4 weeks of treatment, and oral iron should be continued for 3 months after hemoglobin normalizes to fully replenish iron stores 41, 42, 43

Switching to Intravenous Iron

• Intolerance to at least two different oral iron preparations, failure of ferritin levels to improve after 4 weeks of compliant oral therapy, or specific malabsorption conditions are indications to switch to intravenous iron 41, 43

Practical Algorithm for Iron Formulation Selection

• The treatment algorithm starts with ferrous sulfate 200 mg once daily as first-line therapy, with addition of vitamin C 500 mg and consideration of ferrous gluconate or intravenous iron if necessary 41, 42, 43

Management of Iron Deficiency Anemia

Initial Oral Iron Therapy

• The American Gastroenterological Association recommends starting with oral ferrous sulfate 200 mg once daily, which is the preferred first-line treatment due to its effectiveness and low cost, and add vitamin C 500 mg to enhance absorption 44
• Ferrous sulfate is the preferred formulation because it is the least expensive option with no therapeutic advantage of any other oral iron preparation 44
• Prescribe ferrous sulfate 200 mg (containing 65 mg elemental iron) once daily—never multiple times per day 44, 45
• Once-daily dosing improves tolerance while maintaining equal or better iron absorption compared to multiple daily doses due to hepcidin regulation 44
• Every-other-day dosing may be better tolerated for some patients with similar rates of iron absorption 44
• Add vitamin C (ascorbic acid) 500 mg with each iron dose to improve absorption 44
• Alternative formulations (ferrous fumarate or ferrous gluconate) are equally effective if ferrous sulfate is not tolerated 44, 45

Expected Response and Monitoring

• Check hemoglobin at 4 weeks, expecting a rise of approximately 2 g/dL 45
• Continue oral iron for 3 months after hemoglobin normalizes to fully replenish iron stores 45, 46
• Monitor hemoglobin and red cell indices every 3 months for the first year, then again after another year 45

When to Switch to Intravenous Iron

• Use intravenous iron if the patient does not tolerate oral iron, ferritin levels do not improve with a trial of oral iron, or the patient has a condition in which oral iron is not likely to be absorbed 44
• Intolerance to at least two different oral iron preparations is an indication for IV iron 44
• Active inflammatory bowel disease with hemoglobin <10 g/dL is an indication for IV iron 44, 47
• Post-bariatric surgery patients with disrupted duodenal iron absorption should receive IV iron 44, 47
• Celiac disease with inadequate response to oral iron despite gluten-free diet adherence may require IV iron 44
• Chronic kidney disease with functional iron deficiency (ferritin 100-300 ng/mL with transferrin saturation <20%) may require IV iron 45
• Chronic heart failure with iron deficiency (ferritin <100 ng/mL or 100-300 ng/mL with transferrin saturation <20%) may require IV iron 45, 47

Intravenous Iron Formulations

• Prefer IV iron formulations that can replace iron deficits with 1-2 infusions rather than those requiring more than 2 infusions 44
• All IV iron formulations have similar overall safety profiles; true anaphylaxis is very rare (0.6-0.7%) 44
• Most reactions are complement activation-related pseudo-allergy (infusion reactions) that respond to slowing the infusion rate 44

Special Population Considerations

• In patients with inflammatory bowel disease, determine whether iron deficiency is due to inadequate intake/absorption or gastrointestinal bleeding 44
• Treat active inflammation effectively to enhance iron absorption or reduce iron depletion in patients with inflammatory bowel disease 44
• Use IV iron as first-line treatment when hemoglobin <10 g/dL with active inflammation in patients with inflammatory bowel disease 44, 47
• In patients with chronic kidney disease, functional iron deficiency is common and defined by ferritin 100-300 ng/mL with transferrin saturation <20% 45
• IV iron is preferred for dialysis patients; either IV or oral iron for non-dialysis CKD stages 3-5 45
• In patients with chronic heart failure, screen for iron deficiency with ferritin and transferrin saturation 47
• IV iron improves symptoms and quality of life in heart failure with functional iron deficiency 45, 47
• In patients with post-bariatric surgery, IV iron is preferred due to disrupted duodenal absorption mechanisms 44, 47
• In patients with celiac disease, ensure adherence to gluten-free diet to improve iron absorption 44
• Consider oral iron supplementation based on severity of iron deficiency and patient tolerance in patients with celiac disease 44
• Progress to IV iron if iron stores do not improve despite dietary compliance in patients with celiac disease 44

Iron Deficiency Anemia Treatment

Evidence-Based Recommendations

• The American Gastroenterological Association and other societies imply that ferrous pyrophosphate is not a recommended treatment option for iron deficiency anemia, as it is not mentioned in major clinical guidelines 48, 49

Treatment Alternatives

• Ferrous ascorbate may be considered as an alternative to ferrous sulfate, although it offers no proven superiority, and its methodological quality of evidence is very low 48, 49

Iron Deficiency Anemia Treatment Guidelines

Diagnostic Criteria and Treatment Approach

• The American Gastroenterological Association recommends iron supplementation immediately upon diagnosis of iron deficiency anemia, defined as low hemoglobin with ferritin <30 μg/L, regardless of whether the underlying cause has been fully identified 50
• In the presence of inflammation, ferritin <100 μg/L with transferrin saturation <20% indicates iron deficiency anemia requiring treatment 50
• The European Crohn's and Colitis Organisation suggests treating iron deficiency without anemia in conditions like chronic heart failure, but evidence is limited in other contexts 50

First-Line Treatment Approach

• The American College of Gastroenterology recommends starting oral ferrous sulfate 200 mg once daily immediately upon diagnosis, without delaying treatment while awaiting diagnostic workup 51
• Ferrous sulfate 200 mg (65 mg elemental iron) once daily is the preferred first-line treatment due to effectiveness and low cost 52, 51
• Adding vitamin C (ascorbic acid) 500 mg with each iron dose enhances absorption, especially when transferrin saturation is severely low 52, 51

Expected Response and Monitoring

• Check hemoglobin at 4 weeks, expecting a rise of approximately 2 g/dL 50, 52
• Continue oral iron for 3 months after hemoglobin normalizes to fully replenish iron stores 52

When to Switch to Intravenous Iron

• Intravenous iron should be considered as first-line treatment in specific clinical scenarios, such as active inflammatory bowel disease with hemoglobin <10 g/dL 50
• The American Gastroenterological Association suggests using IV iron as first-line when hemoglobin <10 g/dL with active inflammation 50
• Choose IV iron preparations that replace iron deficits in 1-2 infusions, rather than multiple infusions, to minimize risk 53, 51

Special Population Considerations

• In premenopausal women, assess menstrual blood loss first, and screen for celiac disease with antiendomysial antibody and IgA measurement before pursuing endoscopy 52, 51
• In pregnant women, start oral low-dose iron 30 mg/day at first prenatal visit for prevention, and treat anemia with 60-120 mg/day elemental iron 54
• In critically ill patients with iron deficiency confirmed by low hepcidin levels, administer 1 g of IV iron as a single dose using carbohydrate-bound formulations 53

Critical Pitfalls to Avoid

• Do not prescribe multiple daily doses of oral iron, as this increases side effects without improving efficacy due to hepcidin-mediated absorption blockade 52
• Do not stop iron therapy when hemoglobin normalizes, but continue for 3 months to replenish stores 52
• Do not overlook vitamin C supplementation when oral iron response is suboptimal 52, 51

Managing Iron-Deficiency Anemia with Concurrent Chronic Inflammation

Diagnostic Approach

• The European Crohn's and Colitis Organisation recommends differentiating pure anemia of chronic disease from combined iron deficiency anemia plus anemia of chronic disease, as inflammation elevates ferritin independently of iron stores 55, 56
• In the presence of biochemical or clinical inflammation, ferritin 30-100 μg/L with transferrin saturation <20% indicates combined true iron deficiency and anemia of chronic disease 55
• Ferritin <30 μg/L indicates absolute iron deficiency regardless of inflammation 56

Treatment Algorithm

• The European Crohn's and Colitis Organisation recommends intravenous iron as first-line therapy for patients with active inflammation and hemoglobin <10 g/dL, as oral iron absorption is severely impaired by inflammation-induced hepcidin elevation 55, 57
• Intravenous iron is more effective (odds ratio 1.57 for achieving 2.0 g/dL hemoglobin increase) and better tolerated (lower discontinuation rates) than oral iron in inflammatory conditions 57
• For patients with mild anemia (hemoglobin >10 g/dL) and clinically inactive disease, oral iron may be appropriate if disease is truly quiescent 57, 56

Expected Response and Monitoring

• Hemoglobin should rise by approximately 2 g/dL within 4 weeks of treatment, representing an acceptable speed of response regardless of route 55
• Patients in remission should be monitored every 12 months, while patients with mild disease should be monitored every 6 months 56

Special Considerations

• In inflammatory bowel disease, iron supplementation should be initiated when iron deficiency anemia is present, with intravenous iron preferred for active disease 55, 56
• The American Gastroenterological Association and the European Crohn's and Colitis Organisation recommend checking for vitamin B12 and folate deficiency at least annually or if macrocytosis is present 56, 58

Treatment Duration for Iron Deficiency Anemia

Critical Corrections to Treatment Regimen

• The American Gastroenterological Association recommends continuing iron supplementation for 3 months after hemoglobin normalizes, not stopping at 6 months regardless of response 59, 60
• Total treatment time typically totals 6-7 months, which includes the time to normalize hemoglobin (typically 3-4 months) plus 3 additional months to replenish stores 59, 60

Expected Response and Monitoring

• Hemoglobin should rise by approximately 2 g/dL after 3-4 weeks of treatment, indicating a positive response to iron supplementation 59, 60
• The American College of Gastroenterology recommends monitoring hemoglobin and red cell indices every 3 months for the first year after completing therapy, and again after another year 59, 60

Special Considerations

• The American College of Obstetricians and Gynecologists recommends assessing menstrual blood loss first in menstruating women, as menorrhagia, pregnancy, and breastfeeding account for iron deficiency in 5-10% of menstruating women 59, 60
• In women under 45 years without upper GI symptoms, endoscopy is not indicated, according to the American Gastroenterological Association 59, 60

Treatment Adjustments

• If oral iron supplementation is not tolerated, alternative formulations (ferrous gluconate or ferrous fumarate) are equally effective, as recommended by the American Gastroenterological Association 59
• The American College of Gastroenterology recommends considering intravenous iron if there is intolerance to at least two different oral iron preparations, or if ferritin levels fail to improve after 4 weeks of compliant oral therapy 59

Iron Deficiency Treatment Guidelines

Expected Response and Treatment Duration

• Hemoglobin should rise by approximately 2 g/dL after 3-4 weeks of treatment, according to the American College of Cardiology, with a strength of evidence based on clinical trials 61, 62
• The American College of Cardiology recommends continuing oral iron for 3 months after hemoglobin normalizes to fully replenish iron stores, with a total treatment duration of typically 6-7 months 61, 62

When to Switch to Intravenous Iron

• The American Gastroenterological Association suggests that intravenous iron should replace oral therapy in cases of intolerance to at least two different oral iron preparations, despite trying ferrous sulfate, ferrous fumarate, and ferrous gluconate, with a strength of evidence based on clinical trials 61, 63
• The American College of Cardiology recommends intravenous iron for patients with active inflammatory bowel disease and hemoglobin <10 g/dL, as inflammation-induced hepcidin elevation severely impairs oral iron absorption, with a strength of evidence based on clinical trials 61, 62, 64
• The American Gastroenterological Association suggests that intravenous iron is indicated for post-bariatric surgery patients due to disrupted duodenal absorption mechanisms, with a strength of evidence based on clinical trials 63
• The American College of Cardiology recommends intravenous iron for patients with celiac disease and inadequate response to oral iron, despite strict gluten-free diet adherence, with a strength of evidence based on clinical trials 63
• The American Heart Association suggests that intravenous iron improves symptoms and quality of life in patients with chronic heart failure and iron deficiency, with a strength of evidence based on clinical trials 62
• The American Gastroenterological Association recommends intravenous iron for patients with ongoing gastrointestinal blood loss exceeding oral replacement capacity, with a strength of evidence based on clinical trials 63

Preferred IV Iron Formulations

• The American Society of Hematology suggests choosing IV iron preparations that replace iron deficits in 1-2 infusions rather than multiple infusions, to minimize risk and improve convenience, with a strength of evidence based on clinical trials 65
• Ferric carboxymaltose (500-1000 mg single doses delivered within 15 minutes) is a preferred formulation, according to the American Society of Hematology, with a strength of evidence based on clinical trials 65

Special Population Considerations

• The American Gastroenterological Association recommends IV iron as first-line treatment for patients with inflammatory bowel disease and hemoglobin <10 g/dL, as oral iron is poorly absorbed and may worsen inflammation, with a strength of evidence based on clinical trials 61, 62, 64
• The American College of Cardiology suggests that oral iron may be appropriate for patients with mild anemia (hemoglobin >10 g/dL) and clinically inactive disease, with a strength of evidence based on clinical trials 61, 64

Contraindications to Iron Tablets in Iron Deficiency Anemia

Absolute Contraindications

• Patients with active inflammatory bowel disease should not receive oral iron tablets because inflammation-induced hepcidin elevation severely impairs intestinal iron absorption 66, 67
• In patients with active inflammatory bowel disease and hemoglobin <10 g/dL, intravenous iron is first-line therapy, not oral iron 66, 67, 68
• The European Society of Gastrointestinal Endoscopy recommends that iron replacement therapy should not be deferred while awaiting investigations unless colonoscopy is imminent, as iron can interfere with visualization 69, 70

Relative Contraindications and Cautions

• The American Gastroenterological Association suggests that oral iron is contraindicated when rapid correction is needed for severe, symptomatic iron deficiency anemia with circulatory compromise 70, 69
• In cases of severe symptomatic iron deficiency anemia with circulatory compromise, packed red cell transfusion followed by iron replacement, preferably intravenous, is appropriate 69, 70
• The National Institute for Health and Care Excellence recommends that post-bariatric surgery patients, those with celiac disease and ongoing gluten exposure, and patients with chronic kidney disease and functional iron deficiency should prefer intravenous iron due to impaired oral iron absorption 67, 68

Clinical Algorithm for Oral Iron Use

• If active inflammatory bowel disease or other inflammatory condition with hemoglobin <10 g/dL is present, use intravenous iron, not oral, as recommended by the American College of Gastroenterology 66, 67
• If post-bariatric surgery, prefer intravenous iron, as suggested by the Clinical Gastroenterology and Hepatology society 67
• If colonoscopy is scheduled within days, defer oral iron, as recommended by the European Society of Gastrointestinal Endoscopy 69, 70
• If severe symptomatic iron deficiency anemia with hemodynamic instability is present, use transfusion and intravenous iron, not oral, as recommended by the American Heart Association 70

Common Pitfalls to Avoid

• Do not prescribe oral iron to patients with active inflammatory bowel disease, especially if hemoglobin <10 g/dL, as this is ineffective and potentially harmful, according to the American Gastroenterological Association 66, 67
• Do not continue oral iron in patients who fail to respond after 4 weeks, reassess for malabsorption, inflammation, or ongoing blood loss, and switch to intravenous iron, as recommended by the National Institute for Health and Care Excellence 69, 70
• Do not exceed 100 mg elemental iron daily in patients with inactive inflammatory bowel disease, as higher doses may trigger inflammation, according to the European Crohn’s and Colitis Organisation 66

Iron Deficiency Anemia Treatment Guidelines

Diagnosis and Treatment

• The American Gastroenterological Association recommends starting oral ferrous sulfate 200 mg once daily immediately for patients with clear iron deficiency anemia requiring treatment 71
• Iron saturation of 8% indicates profound iron depletion, and ferritin of 11 ng/mL confirms absolute iron deficiency, according to the American Journal of Kidney Diseases and Clinical Gastroenterology and Hepatology 72, 71
• The combination of transferrin saturation <20% and ferritin <30 ng/mL definitively establishes iron deficiency requiring supplementation, as stated by the American Journal of Kidney Diseases and Clinical Gastroenterology and Hepatology 72, 71

Treatment Protocol

• The American College of Gastroenterology recommends prescribing ferrous sulfate 200 mg (65 mg elemental iron) once daily, and taking it on an empty stomach for optimal absorption 71, 73
• Adding vitamin C (ascorbic acid) 500 mg with each iron dose is critical for patients with severely low saturation, as recommended by Clinical Gastroenterology and Hepatology 71, 73
• Avoiding tea and coffee within 1 hour of taking iron is recommended, as these can inhibit absorption, according to Clinical Gastroenterology and Hepatology 73

Monitoring and Follow-up

• Checking hemoglobin at 4 weeks and expecting a rise of approximately 2 g/dL is recommended, as stated by Clinical Gastroenterology and Hepatology 71, 73
• Continuing oral iron for 3 months after hemoglobin normalizes to fully replenish iron stores is recommended, according to Clinical Gastroenterology and Hepatology 71, 73

Switching to Intravenous Iron

• Switching to IV iron is recommended if there is intolerance to at least two different oral iron preparations, or if ferritin levels fail to improve after 4 weeks of compliant oral therapy, as stated by Clinical Gastroenterology and Hepatology 71, 73
• Prefering formulations that replace deficits in 1-2 infusions, such as ferric carboxymaltose 500-1000 mg, is recommended, according to Clinical Gastroenterology and Hepatology 71, 73

Treatment of Iron Deficiency Anemia

Immediate Treatment Protocol

• Oral iron supplementation is first-line therapy for patients with moderate anemia, as defined by the World Health Organization, with hemoglobin levels between 8.0-10.9 g/dL, according to the American College of Sports Medicine 74, 75

Addressing the Underlying Cause

• Gastrointestinal endoscopy is not indicated in women under 45 years without upper GI symptoms, alarm features, or family history of colon cancer, as recommended by the American Gastroenterological Association 76

Oral Iron Therapy and Transition to Intravenous Iron in Iron‑Deficiency Anemia

First‑Line Oral Iron Regimen

Monitoring and Expected Response

Indications for Intravenous Iron

Absolute Indications

Relative Indications

Preferred Intravenous Iron Formulations and Safety

Blood Transfusion Guidance

Special Considerations in Inflammatory Bowel Disease

Clinical Pitfalls to Avoid

Algorithm for Non‑Response to Oral Iron

Management of Iron‑Deficiency Anemia in Patients Using Proton‑Pump Inhibitors

Effect of PPI Therapy on Iron Absorption

• Long‑term proton‑pump inhibitor (PPI) use reduces gastric acid secretion, impairing the conversion of dietary non‑heme iron to absorbable ferrous iron and thereby contributing to iron deficiency. 79, 80
• Because PPIs impair iron absorption, clinicians should consider intravenous iron when oral supplementation fails, while still addressing the underlying indication for PPI therapy. 79, 80

Need for Comprehensive Gastrointestinal Evaluation

• In adult men and post‑menopausal women on PPIs, a full gastrointestinal work‑up—including upper endoscopy and colonoscopy—is required to exclude occult bleeding sources; PPI use does not eliminate the need for cancer screening. 79, 80, 81
• Celiac disease should be screened for with anti‑endomysial antibodies and IgA measurement, as it is a common malabsorption cause that may coexist with PPI therapy. 79, 80
• Microscopic hematuria should be checked to rule out renal tract pathology as a potential source of chronic blood loss. 79, 80
• Additional contributors to negative iron balance—such as menstrual blood loss, blood donation, inadequate dietary intake, chronic NSAID use, and prior gastrointestinal surgery—must be assessed. 79, 80

Guidance on Continuing or Modifying PPI Therapy

• The PPI should not be discontinued without first addressing its underlying indication (e.g., gastro‑esophageal reflux disease, peptic ulcer disease, Barrett’s esophagus). 79, 80
• Clinicians must not attribute iron deficiency solely to PPI use until a complete gastrointestinal investigation has excluded malignancy and other bleeding sources. 79, 80, 81, 82

Diagnostic Algorithm for Non‑Response to Oral Iron in PPI Users

• If oral iron fails, repeat endoscopic evaluation or video capsule endoscopy should be performed to detect ongoing occult bleeding. 79, 80
• Malabsorption syndromes—including celiac disease, inflammatory bowel disease, and post‑bariatric‑surgery anatomy—should be considered as alternative explanations for persistent iron deficiency. 79, 80
• Concurrent vitamin B12 or folate deficiencies, which can coexist with PPI‑related malabsorption, should be screened for. 79, 80

Long‑Term Monitoring and Re‑assessment

• The necessity of ongoing PPI therapy should be reviewed at least annually, because prolonged use increases the risk of recurrent iron deficiency. 79, 80

Intravenous Iron Use in Patients with Peptic Ulcer Disease

Absolute Indications for Switching to IV Iron

• In patients with active peptic ulcer disease and a hemoglobin level below 10 g/dL, rapid correction of anemia is recommended, prompting the use of intravenous iron rather than continued oral therapy. [83][84]85

Preferred IV Iron Formulations

• Ferric carboxymaltose can be administered as 750–1000 mg per 15‑minute infusion; two doses given at least 7 days apart provide a total of 1500 mg, allowing iron repletion in 1–2 sessions. 86
• Ferric derisomaltose is approved for a single 1000 mg infusion, offering complete iron replacement in one visit. 86

Safety Considerations for IV Iron Choice

• Iron dextran is not recommended as first‑line IV iron in this population because it carries a higher risk of anaphylactic reactions (approximately 0.6–0.7 % incidence of true anaphylaxis with IV iron agents). 86

Diagnostic Criteria for Iron Deficiency

1. Definitions Without Inflammation

• Serum ferritin < 30 µg/L defines iron deficiency in patients who have no biochemical or clinical evidence of inflammation. 87
• Transferrin saturation < 16 % is a sensitive indicator of iron deficiency, although its specificity is low. 87
• Ferritin < 15 µg/L indicates absolute iron deficiency with very high specificity (≈ 99 %). 87

2. Definitions With Inflammation

• Ferritin < 100 µg/L is the appropriate lower limit for normal iron stores when inflammation is present, because ferritin behaves as an acute‑phase reactant. 87
• Ferritin 30–100 µg/L together with transferrin saturation < 16 % suggests a mixed picture of true iron deficiency plus anemia of chronic disease. 87
• Ferritin > 100 µg/L together with transferrin saturation < 16 % defines anemia of chronic disease (also called anemia of inflammation). 87

3. Overall Diagnostic Algorithm (Applicable to All Populations)

• In patients without inflammation, diagnose iron deficiency when serum ferritin < 30 µg/L or transferrin saturation < 16 %. 88
• In patients with inflammation, diagnose iron deficiency when ferritin < 100 µg/L and transferrin saturation < 20 %. 88

Note: The strength of evidence for the ferritin < 15 µg/L cutoff is high specificity (≈ 99 %).

Guideline Recommendations for Management of Iron Deficiency Anemia

First‑Line Oral Iron Therapy

Monitoring Response to Oral Iron

Indications for Switching to Intravenous Iron

Preferred Intravenous Iron Formulations

Diagnostic Workup for Confirmed Iron Deficiency Anemia

Special Population Considerations

Inflammatory Bowel Disease

Chronic Heart Failure

Pregnancy

Post‑Bariatric Surgery

Celiac Disease

Safety and Pitfalls (Cited Recommendations)

Oral Iron Management After Acute Upper Gastrointestinal Bleeding

Initiation Timing and Indications

Dosing Regimen and Adjuncts

Monitoring and Treatment Duration

Criteria for Switching to Intravenous Iron

Preferred Intravenous Iron Formulations

Critical Pitfalls to Avoid

Iron Deficiency Anemia – Evidence‑Based Diagnosis and Management

Diagnosis

• A ferritin level < 15 ng/mL (e.g., 14 ng/mL) has 99 % specificity for absolute iron deficiency, confirming the diagnosis. 95
• Hemoglobin < 12 g/dL in women (e.g., 11.2 g/dL) meets WHO criteria for anemia and supports the diagnosis of iron‑deficiency anemia. 96

Immediate Oral Iron Therapy

• Initiate oral ferrous sulfate 200 mg (≈65 mg elemental iron) once daily without waiting for further work‑up. 95
• Administer the dose on an empty stomach for maximal absorption; if gastrointestinal irritation occurs, it may be taken with food. 95
• Co‑administer vitamin C ≈ 500 mg with each iron dose to enhance absorption, especially when transferrin saturation is markedly low (≈12 %). 95
• Once‑daily dosing is superior to multiple daily doses because hepcidin remains elevated for ~48 h after iron ingestion, blocking additional absorption and increasing side‑effects without improving efficacy. 95
• If ferrous sulfate is not tolerated, ferrous fumarate (≈106 mg elemental iron) or ferrous gluconate (≈38 mg elemental iron) provide comparable efficacy. 95

Expected Hematologic Response & Monitoring

• Check hemoglobin 4 weeks after starting therapy; an increase of ≈2 g/dL (≥10 g/L) is expected. 95
• Continue oral iron for 3 months after hemoglobin normalizes to fully replenish iron stores; total treatment duration is typically 6–7 months. 95
• Perform hemoglobin and red‑cell index monitoring every 3 months during the first year, then repeat after an additional year. 95

Investigation of Underlying Cause

• Adult men and post‑menopausal women: Perform urgent bidirectional endoscopy (upper endoscopy + colonoscopy) because iron deficiency may be the sole manifestation of gastrointestinal malignancy. 95
• Premenopausal women:
  
  • First assess menstrual blood loss; menorrhagia, pregnancy, and breastfeeding account for iron deficiency in 5–10 % of menstruating women. 95
  • Screen for celiac disease with tissue transglutaminase IgA antibodies; celiac disease is present in 3–5 % of iron‑deficiency cases and can cause treatment failure if missed. 95
  • Test for Helicobacter pylori using stool antigen or urea‑breath test. 95
• Reserve bidirectional endoscopy for patients who:
  
  • Are ≥ 50 years old,
  • Have gastrointestinal symptoms (abdominal pain, altered bowel habits, overt bleeding),
  • Have positive celiac or H. pylori testing requiring confirmation,
  • Fail to respond to adequate oral iron after 8–10 weeks, or
  • Have a strong family history of colorectal cancer. 95

Indications to Switch to Intravenous Iron

• Intolerance to ≥ two different oral iron formulations (ferrous sulfate, fumarate, or gluconate). 95
• Ferritin does not improve after 4 weeks of compliant oral therapy. 95
• Active inflammatory bowel disease with hemoglobin < 10 g/dL (hepcidin‑mediated absorption blockade). 95
• Post‑bariatric surgery patients (duodenal absorption disrupted). 95
• Celiac disease with inadequate response despite strict gluten‑free diet adherence. 95
• Ongoing gastrointestinal blood loss that exceeds the replacement capacity of oral iron. 95

Preferred Intravenous Iron Formulations

All IV regimens aim to replace the iron deficit in 1–2 infusions to minimize risk and improve convenience. 95

Critical Pitfalls to Avoid

• Do not prescribe multiple daily oral doses; this raises side‑effects without added benefit because hepcidin blocks subsequent absorption. 95
• Do not discontinue iron therapy when hemoglobin normalizes; continue for an additional 3 months to restore stores. 95
• Do not persist with oral iron beyond 4 weeks without a hemoglobin rise; reassess for malabsorption, ongoing loss, or need for IV iron. 95
• Do not overlook vitamin C supplementation when the oral response is suboptimal. 95
• Do not miss celiac disease screening; its prevalence of 3–5 % in iron‑deficiency cases can lead to treatment failure if undetected. 95
• Do not delay endoscopic evaluation in high‑risk patients (age ≥ 50, alarm symptoms, or treatment failure), as gastrointestinal malignancy may present solely with iron deficiency. 95

Management of Iron‑Deficiency Anemia with Hemoglobin ≈ 9.4 g/dL

Oral Iron Therapy

• Adding 500 mg vitamin C to each dose of oral ferrous sulfate markedly improves iron absorption, which is especially important in patients with moderate‑to‑severe anemia (Hb ≈ 9.4 g/dL). 97

Expected Hemoglobin Response and Monitoring

• In adult patients receiving daily oral ferrous sulfate, hemoglobin is expected to increase by about 2 g/dL after 4 weeks (e.g., from 9.4 g/dL to ≈ 11.4 g/dL). 97
• After hemoglobin normalizes, oral iron should be continued for an additional 3 months to fully replenish iron stores, resulting in a total treatment duration of roughly 6–7 months. 97

Criteria for Switching to Intravenous Iron

• Intravenous iron is indicated when a patient cannot tolerate at least two different oral iron formulations (e.g., ferrous sulfate and ferrous fumarate or gluconate). 97
• In patients with active inflammatory bowel disease and hemoglobin < 10 g/dL, intravenous iron is preferred because inflammation‑driven hepcidin elevation markedly reduces oral iron absorption. 97

Special Population: Inflammatory Bowel Disease

• For adults with active inflammatory bowel disease and hemoglobin < 10 g/dL, intravenous iron should be used as first‑line therapy, as oral iron is poorly absorbed and may exacerbate intestinal inflammation. 97

Blood Transfusion Thresholds

• In a patient with hemoglobin ≈ 9.4 g/dL, red‑cell transfusion is not indicated unless there is symptomatic anemia with hemodynamic instability, acute coronary syndrome, or acute myocardial infarction. 98
• For asymptomatic, hemodynamically stable chronic anemia without acute coronary syndrome, a restrictive transfusion threshold of hemoglobin 7–9 g/dL is recommended. 98

Iron Therapy Guidelines for Iron‑Deficiency Anemia

1. Oral Iron Therapy – Dosing and Adjuncts

• Adding 500 mg of vitamin C to each oral iron dose markedly improves iron absorption, especially when transferrin saturation is very low. 99
• When ferrous sulfate is not tolerated, ferrous fumarate (≈106 mg elemental iron) or ferrous gluconate (≈38 mg elemental iron) provide comparable efficacy, though at higher cost. 99

2. Expected Hemoglobin Response and Treatment Duration

• In adherent patients, hemoglobin is expected to rise by about 2 g/dL after 3–4 weeks of oral iron therapy. [99][100]
• After hemoglobin normalizes, oral iron should be continued for an additional 3 months to fully replenish iron stores, resulting in a total treatment course of 6–7 months. 99
• Hemoglobin and red‑cell indices should be monitored every 3 months during the first year, then again after another year of follow‑up. 99

3. Intravenous Iron – Absolute Indications

• Active inflammatory bowel disease (IBD) with hemoglobin < 10 g/dL: IV iron is first‑line because inflammation‑induced hepcidin markedly reduces oral absorption. 100
• Documented intolerance to at least two different oral iron formulations (e.g., ferrous sulfate and ferrous fumarate) warrants IV iron. 99

4. Intravenous Iron – Efficacy in IBD

• In patients with active IBD and hemoglobin < 10 g/dL, IV iron yields a higher likelihood of achieving a ≥ 2.0 g/dL hemoglobin increase (odds ratio ≈ 1.57) and is better tolerated than oral iron. 100
• For mild anemia (hemoglobin > 10 g/dL) in quiescent IBD, oral iron may be used if adequate absorption is anticipated. 100

5. Preferred IV Iron Formulations and Safety Measures

• IV iron products that can replenish the iron deficit in 1–2 infusions are preferred to minimize infusion‑related risk and improve convenience. 99
• Iron dextran is not recommended as a first‑line IV agent because it carries a higher anaphylaxis risk (≈ 0.6–0.7 %); true anaphylaxis with any IV iron is rare. 99
• Most infusion reactions are pseudo‑allergic (complement activation) and can be mitigated by slowing the infusion rate. 99
• IV iron must be administered in a setting equipped with resuscitation equipment. 99

6. Critical Management Errors to Avoid

• Do not discontinue iron therapy when hemoglobin normalizes; continue for an additional 3 months to restore iron stores. 99
• Do not omit vitamin C supplementation when oral iron response is suboptimal. 99
• Do not fail to identify and treat the underlying cause of iron deficiency while providing supplementation. 99

Intravenous Iron Management in Inflammatory Bowel Disease

Absolute Indications

• In patients with active inflammatory bowel disease (IBD) and hemoglobin < 10 g/dL, intravenous (IV) iron is recommended as first‑line therapy because oral iron is poorly absorbed and may exacerbate intestinal inflammation. 101

Relative Indications / Oral Iron Use

• For individuals with mild anemia (hemoglobin > 10 g/dL) and clinically inactive IBD, oral iron may be considered provided the disease is truly quiescent. 101
• In IBD patients, elemental iron doses should not exceed 100 mg per day, as higher oral doses have been associated with triggering intestinal inflammation. 101

Re‑treatment Thresholds After Successful IV Iron

• Following successful IV iron therapy in IBD, repeat iron supplementation should be initiated when serum ferritin falls below 100 µg/L or hemoglobin drops below 12 g/dL in women or 13 g/dL in men. 101

Monitoring Schedule

• After correction of iron deficiency in IBD, monitor for recurrence every 3 months for at least one year, then every 6–12 months thereafter. 101

Initiating Intravenous Iron Monoferric After Blood Transfusion in Iron‑Deficiency Anemia

Iron Availability After Red‑Cell Transfusion

• The iron contained in each transfused red‑cell unit (≈150–280 mg) is not released for erythropoiesis until the cells are phagocytosed after their average lifespan of 100–110 days; in iron‑deficient or inflamed states this recycling is further delayed, making post‑transfusion IV iron beneficial during the subsequent 90‑day period. 102

When Intravenous Iron Should Supersede Oral Iron

• Oral ferrous sulfate (200 mg tablet delivering ≈65 mg elemental iron) remains the cost‑effective first‑line therapy for most iron‑deficiency anemia patients. 103
• Intravenous iron is recommended as first‑line when any of the following are present:

Expected Hematologic Response and Monitoring

• A rise in hemoglobin of roughly 2 g/dL is typically observed within 3–4 weeks after a single IV iron dose. 105
• Hemoglobin and red‑cell indices should be re‑evaluated every 3 months during the first year of therapy, then annually thereafter. 103

Safety and Administration Precautions

• Resuscitation facilities must be readily available whenever IV iron is administered. 103
• All IV iron products share a similar overall safety profile; true anaphylaxis is exceedingly rare (≈0.6–0.7 %). Most infusion reactions are mild complement‑activation pseudo‑allergies that respond to slowing the infusion rate.

Diagnostic Work‑up Should Not Delay Iron Repletion

• Initiation of IV iron should not be postponed while awaiting diagnostic investigations, except when an imminent colonoscopy is planned (iron can impair endoscopic visualization). 103
• All adult men and post‑menopausal women with confirmed iron‑deficiency anemia require bidirectional endoscopy (upper endoscopy + colonoscopy) to exclude gastrointestinal malignancy. 103

Critical Pitfalls to Avoid

• Do not wait for further hemoglobin decline before starting IV iron; the need for transfusion already indicates severe deficiency. 102
• Do not default to oral iron when absolute indications for IV iron (as listed above) are present. 104
• Do not assume that transfused red cells have corrected the underlying iron deficiency, because the iron they contain is not immediately bioavailable. 102

Guidelines for Initiating and Managing Iron Supplementation

Diagnostic Thresholds for Starting Iron

• In individuals without evidence of inflammation, iron therapy should be started when serum ferritin is < 30 ng/mL, irrespective of hemoglobin level. 106
• A transferrin saturation (TSAT) below 16–20 % signals iron deficiency that warrants treatment in the absence of inflammation. 107
• In the presence of inflammation, iron supplementation is indicated when ferritin is < 100 ng/mL and TSAT is < 20 %. [106][107]
• Ferritin values between 30–100 ng/mL combined with low TSAT suggest a mixed picture of absolute iron deficiency and anemia of chronic disease; iron therapy remains indicated. 106

Hemoglobin Thresholds Defining Anemia

• Adult females are classified as anemic when hemoglobin falls below 12.0 g/dL. 107
• Adult males are classified as anemic when hemoglobin falls below 13.0 g/dL. 107
• Children aged 0.5–5 years are considered anemic when hemoglobin is < 11.0 g/dL. 107
• Children aged 5–12 years are considered anemic when hemoglobin is < 11.5 g/dL. 107
• Children aged 12–15 years are considered anemic when hemoglobin is < 12.0 g/dL. 107

Absolute Indications for Intravenous Iron (First‑Line IV Therapy)

• Patients with active inflammatory bowel disease and hemoglobin < 10 g/dL should receive IV iron as the initial treatment because inflammation‑driven hepcidin markedly impairs oral absorption. 106
• Individuals who have undergone bariatric surgery should be managed with IV iron due to disrupted duodenal absorption pathways. 106
• Patients with chronic kidney disease who are on hemodialysis require IV iron as the preferred route of supplementation. 107

Safety Requirements for Intravenous Iron Administration

• All IV iron preparations must be administered in a setting equipped with resuscitation facilities to manage rare anaphylactic reactions. 107

Special Population Considerations

Inflammatory Bowel Disease (IBD)

• For IBD patients with active inflammation and hemoglobin < 10 g/dL, IV iron is the first‑line therapy. 106
• In IBD patients with quiescent disease and mild anemia (hemoglobin > 10 g/dL), oral iron may be used safely. 106
• Re‑initiation of iron therapy is recommended when ferritin drops below 100 ng/mL or when hemoglobin falls below 12 g/dL in females or 13 g/dL in males. 106

Chronic Kidney Disease (CKD)

• Non‑dialysis CKD patients should start iron supplementation when TSAT ≤ 30 % and ferritin ≤ 500 ng/mL, provided they are not receiving erythropoiesis‑stimulating agents. 107
• Hemodialysis patients are best managed with IV iron as the preferred route. 107
• Peritoneal dialysis patients may receive either oral or IV iron based on clinical judgment. 107
• In CKD patients with hemoglobin < 11 g/dL, treatment goals include maintaining ferritin ≥ 100 ng/mL and TSAT ≥ 20 %. 108

Empiric Iron Supplementation in Patients with Low Hemoglobin

Initiation of Therapy

• Start oral ferrous sulfate 200 mg (≈65 mg elemental iron) once daily immediately upon identifying low hemoglobin, without awaiting iron studies, unless a colonoscopy is planned within the next few days. – American Gastroenterological Association guideline (2020), strong recommendation 109
• Do not defer iron replacement while awaiting diagnostic work‑up unless colonoscopy is imminent, because oral iron can obscure endoscopic visualization. – American Gastroenterological Association guideline (2020) 109
• Empiric therapy is justified when low hemoglobin occurs together with a compatible clinical context (e.g., menstruating women, dietary iron insufficiency, obvious chronic blood loss). – American Gastroenterological Association guideline (2020) 109

Diagnostic Criteria for Iron Deficiency

• Ferritin < 30 ng/mL (or < 100 ng/mL in the presence of inflammation) together with transferrin saturation < 20 % definitively confirms iron‑deficiency anemia. – Guideline consensus (American Gastroenterological Association 2020; Clinical Nutrition 2023) 109, 110, 111
• Baseline ferritin measurement helps determine the required duration of therapy and when iron stores are repleted. – American Gastroenterological Association guideline (2020) 109
• Ferritin 30–100 ng/mL with low transferrin saturation suggests a mixed picture of iron‑deficiency anemia and anemia of chronic disease. – Crohn’s & Colitis guideline (2015); Clinical Nutrition 2023 112, 110, 111

Monitoring and Expected Response

• Check hemoglobin after 4 weeks of therapy; a rise of ≈2 g/dL is expected. – American Gastroenterological Association guideline (2020) 109

Situations Requiring Iron Studies Before Starting Therapy

• If a colonoscopy is scheduled within the next few days, obtain iron studies first because oral iron may impair mucosal visualization. – American Gastroenterological Association guideline (2020) 109
• When anemia of chronic disease is suspected (e.g., chronic inflammatory disease, malignancy, chronic kidney disease), perform iron studies before initiating oral iron. – Crohn’s & Colitis guideline (2015); Clinical Nutrition 2023 112, 110, 111

Special Population Considerations

• Premenopausal women: Empiric iron therapy is especially appropriate; menorrhagia, pregnancy, and breastfeeding account for iron deficiency in roughly 5–10 % of menstruating women. – American Gastroenterological Association guideline (2020) 109
• Men and postmenopausal women: Empiric iron may be started, but bidirectional endoscopy (upper endoscopy + colonoscopy) is recommended to exclude gastrointestinal malignancy when iron deficiency is the sole presentation. – American Gastroenterological Association guideline (2020) 109

Management of Severe Iron‑Deficiency Anemia with Hemoglobin ≤ 4 g/dL

1. Immediate Assessment and Stabilization

• Assess cardiovascular stability first; tachycardia, hypotension, chest pain, dyspnea at rest, altered mental status, or acute heart‑failure signs indicate the need for urgent red‑cell transfusion. American College of Cardiology/American Heart Association recommendation. 113
• Obtain baseline iron studies (serum ferritin, transferrin‑saturation, CBC with red‑cell indices) promptly; ferritin < 30 ng/mL and transferrin‑saturation < 16 % confirm absolute iron deficiency. British Society of Gastroenterology guideline. 114

2. Blood‑Transfusion Decision

• Transfuse packed red blood cells only when hemoglobin < 7 g/dL and the patient has hemodynamic instability, symptomatic anemia, or acute coronary syndrome. ACC/AHA guideline (Class IIa). [113][115]
• Signs of circulatory compromise (severe tachycardia, hypotension, altered mental status, acute heart failure) also trigger transfusion at the same hemoglobin threshold. ACC/AHA. [113][115]
• When transfusion is indicated, use a restrictive target of hemoglobin 7–9 g/dL (8–10 g/dL if unstable coronary disease). ACC/AHA. [113][115]
• After any transfusion, administer intravenous iron promptly to correct the underlying iron deficit. ECCO recommendation. 115
• Do not transfuse routinely at hemoglobin 3.8 g/dL in hemodynamically stable patients; intravenous iron is safer and equally effective. ACC/AHA. 113

3. Intravenous Iron as Primary Therapy

• In hemodynamically stable patients with severe anemia, intravenous iron is the first‑line therapy; it yields a clinically meaningful rise in hemoglobin within 7–12 days. British Society of Gastroenterology (expert consensus). 114
• Preferred formulations:
  
  • Ferric carboxymaltose – 750–1000 mg per 15‑minute infusion; two doses ≥ 7 days apart for a total of 1500 mg.
  • Ferric derisomaltose – 1000 mg as a single infusion.
• Iron dextran should be avoided as first‑line because of a higher anaphylaxis risk (≈ 0.6–0.7 %). British Society of Gastroenterology. 114
• Administration must occur in a setting equipped for emergency resuscitation, with monitoring for complement‑activation pseudo‑allergic reactions; infusion rate should be slowed if reactions occur. British Society of Gastroenterology. 116

4. Expected Hemoglobin Response and Monitoring

• Intravenous iron typically raises hemoglobin by ≈ 2 g/dL within 3–4 weeks; meaningful improvement can be observed as early as 7–12 days in severe cases. British Society of Gastroenterology. 114
• Monitoring schedule:
  
  • Repeat hemoglobin 2–4 weeks after the initial IV‑iron dose.
  • Re‑check every 3 months during the first year, then annually thereafter. British Society of Gastroenterology. [116][114]
• Continue iron supplementation for 3 months after hemoglobin normalization to fully replenish iron stores; total treatment duration is usually 6–7 months. British Society of Gastroenterology. [116][114]

5. Investigation of Underlying Cause

• Do not postpone iron therapy while awaiting diagnostic work‑up, unless a colonoscopy is scheduled within days (iron can impair mucosal visualization). British Society of Gastroenterology. 114
• All adult men and post‑menopausal women should undergo bidirectional endoscopy (upper endoscopy + colonoscopy) to exclude gastrointestinal malignancy. British Society of Gastroenterology. 114
• In pre‑menopausal women:
  
  • Evaluate menstrual blood loss first; menorrhagia accounts for iron deficiency in 5–10 % of menstruating women. British Society of Gastroenterology. [116][114]
  • Screen for celiac disease with tissue‑transglutaminase IgA antibodies (present in 3–5 % of iron‑deficiency cases). British Society of Gastroenterology. 114
  • Test for Helicobacter pylori infection. British Society of Gastroenterology. 114
  • Reserve endoscopy for patients ≥ 50 years, those with gastrointestinal symptoms, alarm features, or a family history of colorectal cancer. British Society of Gastroenterology. 114

6. Oral Iron as Adjunct (Not Primary Therapy)

• Once hemoglobin reaches 7–8 g/dL, add oral ferrous sulfate (≈ 200 mg elemental iron once daily) with vitamin C (≈ 500 mg) to enhance absorption. British Society of Gastroenterology. [116][114]
• Avoid multiple daily oral‑iron doses because hepcidin remains elevated for ~48 hours after each dose, blocking absorption and increasing side‑effects without benefit. British Society of Gastroenterology. 114

7. Special Populations

• Inflammatory bowel disease with hemoglobin < 10 g/dL: intravenous iron is mandatory first‑line because inflammation‑driven hepcidin blocks oral absorption. British Society of Gastroenterology and ECCO. [114][115]
• Post‑bariatric surgery patients: use intravenous iron due to disrupted duodenal absorption. British Society of Gastroenterology and ACC/AHA. [114][113]
• Chronic heart failure with iron deficiency (ferritin < 100 ng/mL or 100–300 ng/mL with transferrin‑saturation < 20 %): intravenous iron improves symptoms and quality of life. British Society of Gastroenterology and ACC/AHA. [114][113]

8. Critical Pitfalls to Avoid

• Do not rely on oral iron alone when hemoglobin < 7 g/dL; intravenous iron provides faster, more reliable correction. British Society of Gastroenterology. 114
• Do not transfuse routinely at hemoglobin 3.8 g/dL in stable patients; IV iron is safer and equally effective. ACC/AHA. 113
• Do not discontinue iron therapy when hemoglobin normalizes; continue for at least 3 months to replenish stores. British Society of Gastroenterology. [116][114]
• Do not delay investigation of the underlying cause; gastrointestinal malignancy may present solely with iron deficiency. British Society of Gastroenterology. 114
• Do not miss celiac disease screening in young patients; its prevalence (3–5 %) in iron‑deficiency anemia can cause treatment failure. British Society of Gastroenterology. 114

Guidelines for Diagnosis and Management of Iron‑Deficiency Anemia

Oral Iron Therapy – Dosing and Adjuncts

Expected Hematologic Response and Treatment Duration

Absolute Indications for Intravenous Iron

Preferred Intravenous Iron Formulations

Special Population – Inflammatory Bowel Disease

Diagnostic Work‑up of Underlying Cause

Critical Pitfalls to Avoid

Failure‑to‑Respond Algorithm

Management of Asymptomatic Iron‑Deficiency Anemia in Adults > 40 Years

Immediate Initiation of Therapy

• Start oral ferrous sulfate 200 mg (≈65 mg elemental iron) once daily immediately, together with vitamin C 500 mg per dose, and arrange bidirectional endoscopy to rule out gastrointestinal malignancy. 119

• Oral iron supplementation should not be delayed for further diagnostic work‑up when iron‑deficiency anemia is confirmed. 119

Diagnostic Confirmation of Iron‑Deficiency Anemia

• Ferritin < 30 ng/mL confirms absolute iron deficiency. 119, 120
• Transferrin‑saturation < 20 % indicates iron depletion. 119
• Hemoglobin < 12 g/dL defines anemia in women. 119

Oral Iron Regimen Details

• Ferrous sulfate 200 mg once daily is the most cost‑effective first‑line therapy. 119
• Co‑administration of vitamin C 500 mg with each iron dose enhances absorption, especially when baseline saturation is low. 119
• The dose should be taken on an empty stomach; if gastrointestinal intolerance occurs, it may be taken with food. 119
• Once‑daily dosing is superior to multiple daily doses because hepcidin remains elevated for ~48 h after each dose, limiting further absorption and increasing side‑effects without improving efficacy. 119
• If ferrous sulfate is intolerable, ferrous fumarate or ferrous gluconate are equally effective alternatives. 119

Expected Hematologic Response & Monitoring

• Hemoglobin is expected to rise by ≈2 g/dL after 4 weeks of therapy. 119
• Oral iron should be continued for 3 months after hemoglobin normalizes, giving a total treatment duration of 6–7 months. 119
• Hemoglobin and red‑cell indices should be re‑checked every 3 months during the first year, then annually thereafter. 119

Mandatory Investigation of Underlying Cause

• All women > 40 years with iron‑deficiency anemia require upper and lower gastrointestinal endoscopy to exclude malignancy, regardless of symptom presence. 119, 120, 121
• Menorrhagia accounts for 5–10 % of iron‑deficiency cases in menstruating women; objective assessment (e.g., pictorial blood‑loss scale) is advised when menstrual loss is uncertain. 119
• Celiac disease is present in 3–5 % of iron‑deficiency cases; screening with tissue transglutaminase IgA and total IgA is recommended. 119
• If colonoscopy is scheduled within the next few days, delay oral iron to avoid impaired endoscopic visualization. 119

Adjunctive Nutrient Considerations

• Low‑normal vitamin B12 may blunt hemoglobin response; consider B12 supplementation if hemoglobin fails to rise adequately after 4 weeks. 119
• Adequate folate levels do not require supplementation. 119

Indications for Switching to Intravenous Iron

• Intolerance to ≥ two different oral iron formulations (e.g., ferrous sulfate, fumarate, gluconate). 119
• Ferritin does not improve after 4 weeks of compliant oral therapy. 119
• Hemoglobin fails to increase by ≥ 1 g/dL after 4 weeks. 119
• Confirmed celiac disease with inadequate response despite strict gluten‑free diet adherence. 119

When IV iron is needed, prefer agents that replenish iron stores in 1–2 infusions (e.g., ferric carboxymaltose 750–1000 mg or ferric derisomaltose 1000 mg). 119

Critical Pitfalls to Avoid

• Do not stop iron therapy when hemoglobin normalizes; continue for an additional 3 months to fully replenish stores. 119
• Do not continue oral iron beyond 4 weeks without a hemoglobin rise; reassess for malabsorption, ongoing loss, or need for IV iron. 119
• Do not omit vitamin C supplementation when oral iron response is suboptimal. 119
• Do not neglect gastrointestinal investigation; malignancy may present solely with iron‑deficiency anemia. 119, 120, 121

Failure‑to‑Respond Algorithm (First 6 Months)

• Verify adherence to oral iron therapy.
• Evaluate for ongoing blood loss (repeat endoscopy or video‑capsule endoscopy).
• Consider malabsorption syndromes (celiac disease, inflammatory bowel disease).
• Check for concurrent vitamin B12 or folate deficiency.
• Seek hematology consultation for complex or refractory cases. 119

Guideline Recommendations for Evaluating and Managing Iron‑Deficiency Anemia in Reproductive‑Age Women

Assessment of Menstrual Blood Loss

• In women of reproductive age, use pictorial blood‑loss assessment charts to quantify menstrual bleeding; these tools demonstrate ≈ 80 % sensitivity and specificity for detecting menorrhagia, and menstrual loss (together with pregnancy and breastfeeding) accounts for 5–10 % of iron‑deficiency cases in this population. 122

Screening for Malabsorption (Celiac Disease)

• Celiac disease is identified in 2–3 % of iron‑deficiency anemia cases; therefore, screen all reproductive‑age women with iron deficiency using anti‑endomysial antibodies and total IgA measurement (to rule out IgA deficiency that could render the test falsely negative). 122

Indications for Upper‑Gastrointestinal Endoscopy

• Upper‑GI endoscopy (with possible small‑bowel biopsy) is not recommended for women < 45 years who lack upper‑GI symptoms; it should be reserved for those who present with dyspepsia, reflux, epigastric pain, or other upper‑GI alarm features. 122

Indications for Colonoscopic Evaluation

• Colonoscopy in women < 45 years should be performed only when specific alarm criteria exist, such as rectal bleeding, a first‑degree relative with colorectal cancer, or other concerning gastrointestinal symptoms. 122

Role of Vitamin C as an Adjunct to Oral Iron

• Co‑administration of vitamin C (ascorbic acid) with oral iron preparations enhances iron absorption and should be included when the hematologic response to oral iron is suboptimal. 122

Avoidance of Unnecessary Endoscopic Procedures

• In women < 45 years without upper‑GI symptoms or alarm features, routine gastrointestinal endoscopy is discouraged because menstrual blood loss is the most probable etiology of iron deficiency. 122

Management of Inadequate Response to Oral Iron

• If hemoglobin fails to rise by ≥ 2 g/dL within 4 weeks, first verify adherence to oral therapy, then:

Standard Pediatric Iron Dosing Efficacy

Dosing Considerations

• Standard pediatric iron dosing of 2–3 mg/kg/day elemental iron, given in divided doses, is as effective as a once‑daily regimen of 2 mg/kg/day for treating iron‑deficiency anemia in toddlers, achieving comparable hematologic responses. 123

Iron Management in Non‑Dialysis Chronic Kidney Disease (CKD) Patients with Anemia

Diagnostic Criteria

• Absolute iron deficiency is defined by transferrin saturation (TSAT) ≤ 20 % and serum ferritin ≤ 100 ng/mL in CKD stages 3–5 not on dialysis – this threshold accounts for the inflammatory milieu of CKD and differs from the general population. 124

• CKD‑specific iron‑deficiency thresholds are higher than in the general population because chronic inflammation elevates ferritin independently of iron stores; therefore, ferritin ≥ 100 ng/mL is required to consider iron repletion adequate. 124

Initiation of Iron Therapy

• If hemoglobin (Hb) < 11 g/dL and ferritin < 100 ng/mL or TSAT < 20 %, start iron supplementation (oral or intravenous) to correct anemia. This recommendation follows the KDIGO anemia guideline for CKD. [125][126]

• When Hb ≥ 11 g/dL, iron therapy is generally not indicated unless the patient is receiving or about to start an erythropoiesis‑stimulating agent (ESA). [125][126]

Iron Parameter Targets During Therapy

• Maintain serum ferritin ≥ 100 ng/mL throughout treatment to ensure sufficient iron stores. [125][126]

• Maintain TSAT ≥ 20 % to confirm that iron is readily available for erythropoiesis. [125][126]

Use of Iron With ESA Therapy

• Iron supplementation is essential when ESAs are used, because ESA‑driven erythropoiesis rapidly depletes iron stores. 125

• In patients requiring high ESA doses (≥ 300 IU/kg/week epoetin α or ≥ 1.5 mg/kg/week darbepoetin α) who have ferritin > 800 ng/mL and TSAT < 25 %, consider additional iron therapy to improve hemoglobin response, weighing risks and benefits. [125][126]

Adjusted Ferritin Thresholds for CKD

• Do not apply general‑population ferritin cut‑offs to CKD patients; the CKD‑specific threshold of ≥ 100 ng/mL should be used to avoid under‑treating iron deficiency in the setting of chronic inflammation. 124

Distinguishing Intravenous Iron Therapy from Blood Transfusion

Definition and Classification

• Intravenous iron products are synthetic pharmaceutical compounds in which elemental iron is bound to carbohydrate matrices (e.g., ferric carboxymaltose, ferric derisomaltose, iron sucrose, iron dextran) and contain no human blood cells, plasma, or other blood‑derived components. 127
• Blood products are derived from donated human blood and include packed red blood cells, platelets, plasma, and cryoprecipitate. 128

Mechanisms of Action

• Blood transfusion supplies immediate hemoglobin by delivering intact red blood cells; each unit provides roughly 200 mg of elemental iron that remains unavailable for erythropoiesis until the cells are cleared after a 100–110‑day lifespan. 128
• Intravenous iron directly replenishes iron stores, making iron bioavailable for erythropoiesis within days; a reticulocytosis typically appears 3–5 days after infusion. 127

Clinical Indications

• Blood transfusion is indicated for severe symptomatic anemia with hemodynamic instability, circulatory compromise, or acute coronary syndrome, using restrictive hemoglobin thresholds of 7–9 g/dL (or 8–10 g/dL in unstable coronary disease). 127
• Intravenous iron is the preferred therapy for iron‑deficiency anemia in hemodynamically stable patients, even when hemoglobin is as low as 3.8 g/dL, because it reliably raises hemoglobin within 7–12 days without transfusion‑related risks. 128

Safety Profiles

• Blood transfusion carries multiple risks, including transfusion reactions, alloimmunization, transfusion‑related acute lung injury (TRALI), volume overload, and, in cancer patients, a potential negative impact on long‑term survival. 127
• Intravenous iron has a very low incidence of true anaphylaxis (approximately 0.6–0.7 %); most adverse events are complement‑activation pseudo‑allergies that can be managed by slowing the infusion rate. 127

Clinical Management Recommendations

• When a transfusion is required for acute stabilization, it should be followed immediately by intravenous iron to correct the underlying iron deficit, because transfused red cells do not provide bioavailable iron for ongoing erythropoiesis. 128
• Clinicians should not equate intravenous iron with blood transfusion when counseling patients—especially those with religious or personal objections to blood products—as the interventions differ fundamentally in composition, mechanism, and risk profile. 127
• In stable patients with severe iron‑deficiency anemia, intravenous iron should not be delayed while considering transfusion; IV iron is safer and achieves comparable hemoglobin correction within 1–2 weeks. 128

Diagnostic Criteria and Investigation for Iron Deficiency without Anemia

Laboratory Thresholds for Confirming Iron Deficiency

• Serum ferritin < 30 ng/mL reliably indicates absolute iron deficiency when inflammation is absent, as defined by the British Society of Gastroenterology. 129
• Transferrin saturation < 20 % is a sensitive marker of depleted iron stores, supporting the diagnosis of iron deficiency even with a normal hemoglobin. 130

Recommendations for Endoscopic Evaluation

• In adult men and post‑menopausal women, bidirectional endoscopy (upper endoscopy + colonoscopy) is advised to exclude occult gastrointestinal malignancy, because iron deficiency may be the sole presenting sign. This recommendation follows the British Society of Gastroenterology guidance. 131
• The British Society of Gastroenterology emphasizes that asymptomatic colonic and gastric carcinoma can present with iron‑deficiency anemia, making exclusion of these cancers a priority in evaluation. 129

Contributing Factors to Iron Depletion

• A dietary assessment should be performed to identify iron‑poor diets; however, borderline deficiency alone does not justify foregoing a full investigative work‑up (British Society of Gastroenterology). 132
• Medication review is essential because chronic use of NSAIDs, aspirin, and proton‑pump inhibitors can contribute to iron loss, as highlighted by the British Society of Gastroenterology. 129
• History of gastrointestinal surgery (e.g., gastrectomy, gastric bypass) impairs iron absorption and should be considered a risk factor for iron deficiency (British Society of Gastroenterology). 129

Interaction with Folate Status

• Combined iron and folate deficiency can mask microcytosis by producing an elevated red‑cell distribution width (RDW), a phenomenon described in the British Society of Gastroenterology literature. 132